Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Just as Adverum’s cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy.

Please provide the article or its content so I can generate an SEO-friendly meta description based on your guidelines.

Under the agreement, Lilly will gain control of Adverum’s lead product candidate, Ixo-vec, a Phase 3 gene therapy designed to ...

Eli Lilly said Friday it is set to acquire clinical-stage company Adverum Biotechnologies for up to $12.47 a share, including milestone payments.

Lilly (LLY) to acquire Adverum Biotechnologies (ADVM) for $12.47 per share, with potential CVR payments tied to future ...

Eli Lilly and Company announced a definitive agreement to acquire Aderum Biotechnologies and its leading candidate Ixo-vec. 1 ...

REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted an ...

Adverum Biotechnologies ADVM is developing single-administration gene therapies for highly prevalent ocular diseases, leveraging the potential of its proprietary intravitreal (IVT) platform. Its lead ...

Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life ...